- CorMedix (NASDAQ:CRMD) on Monday said it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath to its facilities in U.S.
- The company expects to initially target the utilization of DefenCath in up to 4,000 patients nationally, that would be prioritized based upon medical need.
- CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024.
- CorMedix anticipates shipments for DefenCath under this agreement to begin in the fourth quarter.
- CRMD is -2.08% to $5.64.
- Source: Press Release
